Find Naporafenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lxh254, 1800398-38-2, Lxh-254, Lxh254 free base, N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, Pan-raf inhibitor lxh254
Molecular Formula
C25H25F3N4O4
Molecular Weight
502.5  g/mol
InChI Key
UEPXBTCUIIGYCY-UHFFFAOYSA-N
FDA UNII
15JL80DG6H

Naporafenib
Naporafenib is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.
1 2D Structure

Naporafenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
2.1.2 InChI
InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
2.1.3 InChI Key
UEPXBTCUIIGYCY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4
2.2 Other Identifiers
2.2.1 UNII
15JL80DG6H
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Lxh254

2.3.2 Depositor-Supplied Synonyms

1. Lxh254

2. 1800398-38-2

3. Lxh-254

4. Lxh254 Free Base

5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

6. Pan-raf Inhibitor Lxh254

7. Naporafenib [inn]

8. 15jl80dg6h

9. 1800398-38-2 (free Base)

10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide

11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-

12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide

13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide

14. Lxh 254

15. K81

16. Unii-15jl80dg6h

17. Naporafenib [who-dd]

18. Chembl4583691

19. Lxh 254 [who-dd]

20. Schembl16094629

21. Bdbm88120

22. Gtpl10658

23. Bcp29080

24. Ex-a1846

25. Nsc807047

26. S8745

27. Akos037648965

28. At23218

29. Nsc-807047

30. Compound 15 [pmid: 31059256]

31. Ac-36207

32. Bl166445

33. Bs-16133

34. Hy-112089

35. Cs-0043317

36. Example 1156 [wo2014151616a1]

37. A16841

38. Us9694016, 1156

2.4 Create Date
2015-02-13
3 Chemical and Physical Properties
Molecular Weight 502.5 g/mol
Molecular Formula C25H25F3N4O4
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass502.18278978 g/mol
Monoisotopic Mass502.18278978 g/mol
Topological Polar Surface Area96.8 Ų
Heavy Atom Count36
Formal Charge0
Complexity709
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


Drugs in Development

read-more
read-more

Details:

ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 18, 2024

blank

01

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 18, 2024

blank

Details:

The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: J.P. Morgan

Deal Size: $184.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 21, 2024

blank

02

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

May 21, 2024

blank

Details:

Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: BofA Securities

Deal Size: $45.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement March 27, 2024

blank

03

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 27, 2024

blank

Details:

The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 14, 2024

blank

04

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Lead Product(s) : Naporafenib,Trametinib

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

Deal Size : Undisclosed

Deal Type : Collaboration

Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

February 14, 2024

blank

Details:

LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 12, 2023

blank

05

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 12, 2023

blank

Details:

ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.


Lead Product(s): Naporafenib,Trametinib

Therapeutic Area: Oncology Brand Name: ERAS-254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 29, 2023

blank

06

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Erasca

U.S.A
arrow
Arvo
Not Confirmed

Details : ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.

Product Name : ERAS-254

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 29, 2023

blank

Details:

LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnostic solid tumors.


Lead Product(s): Naporafenib

Therapeutic Area: Oncology Brand Name: LXH254

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Erasca

Deal Size: $300.0 million Upfront Cash: $300.0 million

Deal Type: Licensing Agreement September 12, 2022

blank

07

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnos...

Product Name : LXH254

Product Type : Other Small Molecule

Upfront Cash : $300.0 million

September 12, 2022

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1800398-38-2 / Naporafenib API manufacturers, exporters & distributors?

Naporafenib manufacturers, exporters & distributors 1

14

PharmaCompass offers a list of Naporafenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naporafenib manufacturer or Naporafenib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naporafenib manufacturer or Naporafenib supplier.

PharmaCompass also assists you with knowing the Naporafenib API Price utilized in the formulation of products. Naporafenib API Price is not always fixed or binding as the Naporafenib Price is obtained through a variety of data sources. The Naporafenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Naporafenib

Synonyms

Lxh254, 1800398-38-2, Lxh-254, Lxh254 free base, N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, Pan-raf inhibitor lxh254

Cas Number

1800398-38-2

Unique Ingredient Identifier (UNII)

15JL80DG6H

About Naporafenib

Naporafenib is an orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.

Naporafenib Manufacturers

A Naporafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naporafenib, including repackagers and relabelers. The FDA regulates Naporafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naporafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Naporafenib Suppliers

A Naporafenib supplier is an individual or a company that provides Naporafenib active pharmaceutical ingredient (API) or Naporafenib finished formulations upon request. The Naporafenib suppliers may include Naporafenib API manufacturers, exporters, distributors and traders.

Naporafenib GMP

Naporafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Naporafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naporafenib GMP manufacturer or Naporafenib GMP API supplier for your needs.

Naporafenib CoA

A Naporafenib CoA (Certificate of Analysis) is a formal document that attests to Naporafenib's compliance with Naporafenib specifications and serves as a tool for batch-level quality control.

Naporafenib CoA mostly includes findings from lab analyses of a specific batch. For each Naporafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Naporafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Naporafenib EP), Naporafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naporafenib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty